During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high dividend payout.



Benzinga readers can review the latest analyst takes on their favorite stocks by visiting Analyst Stock Ratings page. Traders can sort through Benzinga's extensive database of analyst ratings, including by analyst accuracy.



Below are the ratings of the most accurate analysts for three high-yielding stocks in the health care sector.



<h3>Perrigo Company PLC (NYSE:PRGO)</h3>



<ul>
<li>Dividend Yield: 8.83%</li>



<li>Canaccord Genuity analyst Susan Anderson maintained a Buy rating and cut the price target from $40 to $20 on Nov. 6, 2025. This analyst has an accuracy rate of 62%.</li>



<li>JP Morgan analyst Chris Scott downgraded the stock from Overweight to Neutral and slashed the price target from $32 to $20 on Nov. 6, 2025. This analyst has an accuracy rate of 65%.</li>



<li>Recent News: On Nov. 5, Perrigo reported mixed third-quarter financial results and cut its FY25 adjusted EPS guidance below estimates.</li>



<li>Benzinga Pro’s real-time newsfeed alerted to latest PRGO news. </li>
</ul>



<figure class="wp-block-image size-full is-resized"></figure>



<h3>Bristol-Myers Squibb Co (NYSE:BMY)</h3>



<ul>
<li>Dividend Yield: 4.81%</li>



<li>Morgan Stanley analyst Terence Flynn maintained an Underweight rating and cut the price target from $37 to $36 on Dec. 12, 2025. This analyst has an accuracy rate of 69%.</li>



<li>Guggenheim analyst Seamus Fernandez upgraded the stock from Neutral to Buy with a price target of $62 on Dec. 12, 2025. This analyst has an accuracy rate of 81%</li>



<li>Recent News: On Dec. 11, Bristol Myers Squibb received FDA Priority Review for Opdivo Plus AVD combination sBLA in untreated stage III/IV cHL.</li>



<li>Benzinga Pro's real-time newsfeed alerted to latest BMY news </li>
</ul>



<figure class="wp-block-image size-full is-resized"></figure>



<h3>CVS Health Corp (NYSE:CVS)</h3>



<ul>
<li>Dividend Yield: 3.35%</li>



<li>Truist Securities analyst David Macdonald maintained a Buy rating and raised the price target from $95 to $98 on Dec. 10, 2025. This analyst has an accuracy rate of 67%.</li>



<li>UBS analyst Kevin Caliendo maintained a Buy rating and increased the price target from $96 to $97 on Dec. 10, 2025. This analyst has an accuracy rate of 65%</li>



<li>Recent News: On Dec. 9, CVS raised its FY2025 adjusted EPS and sales guidance.</li>



<li>Benzinga Pro’s real-time newsfeed alerted to latest CVS news </li>
</ul>



<figure class="wp-block-image size-full is-resized"></figure>







<figure class="wp-block-embed is-type-video is-provider-youtube wp-block-embed-youtube wp-embed-aspect-16-9 wp-has-aspect-ratio"><div>
 
</div></figure>



Read More: 



<ul>
<li>Top 2 Energy Stocks That May Plunge This Month</li>
</ul>



Photo via Shutterstock

PRGO

Wall Street's top analysts provide insights on three high-dividend healthcare stocks. Perrigo (PRGO) has mixed Q3 results and lowered FY25 EPS guidance. Analysts have mixed ratings with price targets cut to $20. Bristol-Myers Squibb (BMY) received FDA Priority Review for a new treatment, with mixed analyst ratings and price targets between $36 and $62. CVS Health (CVS) raised FY2025 EPS and sales guidance, with analysts maintaining Buy ratings and slightly increasing price targets.

Wall Street's Most Accurate Analysts Give Their Take On 3 Health Care Stocks Delivering High-Dividend Yields